165 related articles for article (PubMed ID: 36602227)
1. Genetic variations predicting progression with docetaxel and novel androgen-receptor pathway inhibitors.
Shiota M; Akamatsu S; Sekine Y; Kimura H; Narita S; Fujimoto N; Terada N; Blas L; Habuchi T; Kamoto T; Momozawa Y; Eto M
Cancer Sci; 2023 Apr; 114(4):1625-1634. PubMed ID: 36602227
[TBL] [Abstract][Full Text] [Related]
2. HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies.
Khalaf DJ; Aragón IM; Annala M; Lozano R; Taavitsainen S; Lorente D; Finch DL; Romero-Laorden N; Vergidis J; Cendón Y; Oja C; Pacheco MI; Zulfiqar M; ; Gleave ME; Wyatt AW; Olmos D; Chi KN; Castro E
Ann Oncol; 2020 Sep; 31(9):1186-1197. PubMed ID: 32574722
[TBL] [Abstract][Full Text] [Related]
3. A common germline variant in CYP11B1 is associated with adverse clinical outcome of treatment with abiraterone or enzalutamide.
Buck SAJ; Meertens M; van Ooijen FMF; Oomen-de Hoop E; de Jonge E; Coenen MJH; Bergman AM; Koolen SLW; de Wit R; Huitema ADR; van Schaik RHN; Mathijssen RHJ
Biomed Pharmacother; 2023 Dec; 169():115890. PubMed ID: 37988848
[TBL] [Abstract][Full Text] [Related]
4. Predictive factors of survival outcomes in first-line therapy for metastatic castration-resistant prostate cancer.
Shiota M; Blas L; Kobayashi S; Matsumoto T; Kashiwagi E; Takeuchi A; Inokuchi J; Shiga KI; Yokomizo A; Eto M
Int J Urol; 2022 Jan; 29(1):26-32. PubMed ID: 34549837
[TBL] [Abstract][Full Text] [Related]
5. The association between missense polymorphisms in SRD5A2 and HSD3B1 and treatment failure with abiraterone for castration-resistant prostate cancer.
Shiota M; Akamatsu S; Narita S; Sumiyoshi T; Fujiwara M; Uchiumi T; Ogawa O; Habuchi T; Eto M
Pharmacogenomics J; 2021 Aug; 21(4):440-445. PubMed ID: 33649516
[TBL] [Abstract][Full Text] [Related]
6. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
[TBL] [Abstract][Full Text] [Related]
7. Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis.
Brasso K; Thomsen FB; Schrader AJ; Schmid SC; Lorente D; Retz M; Merseburger AS; von Klot CA; Boegemann M; de Bono J
Eur Urol; 2015 Aug; 68(2):317-24. PubMed ID: 25108579
[TBL] [Abstract][Full Text] [Related]
8. Differential prognostic impact of complete blood count-related parameters by prior use of novel androgen receptor pathway inhibitors in docetaxel-treated castration-resistant prostate cancer patients.
Kobayashi H; Shiota M; Sato N; Kobayashi S; Matsumoto T; Monji K; Kashiwagi E; Takeuchi A; Inokuchi J; Shiga KI; Yokomizo A; Eto M
Anticancer Drugs; 2022 Jan; 33(1):e541-e547. PubMed ID: 34387597
[TBL] [Abstract][Full Text] [Related]
9. Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents.
Pezaro CJ; Omlin AG; Altavilla A; Lorente D; Ferraldeschi R; Bianchini D; Dearnaley D; Parker C; de Bono JS; Attard G
Eur Urol; 2014 Sep; 66(3):459-65. PubMed ID: 24411987
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of complete blood count parameters in castration-resistant prostate cancer patients treated with androgen receptor pathway inhibitors.
Machidori A; Shiota M; Kobayashi S; Matsumoto T; Monji K; Kashiwagi E; Takeuchi A; Takahashi R; Inokuchi J; Eto M
Urol Oncol; 2021 Jun; 39(6):365.e1-365.e7. PubMed ID: 33077351
[TBL] [Abstract][Full Text] [Related]
11. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone.
Bianchini D; Lorente D; Rodriguez-Vida A; Omlin A; Pezaro C; Ferraldeschi R; Zivi A; Attard G; Chowdhury S; de Bono JS
Eur J Cancer; 2014 Jan; 50(1):78-84. PubMed ID: 24074764
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study.
Sternberg CN; Castellano D; de Bono J; Fizazi K; Tombal B; Wülfing C; Kramer G; Eymard JC; Bamias A; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Poole EM; Ozatilgan A; Geffriaud-Ricouard C; de Wit R
Eur Urol; 2021 Oct; 80(4):497-506. PubMed ID: 34274136
[TBL] [Abstract][Full Text] [Related]
13. The Effect of Treatment Sequence on Overall Survival for Men With Metastatic Castration-resistant Prostate Cancer: A Multicenter Retrospective Study.
Okita K; Hatakeyama S; Narita S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Sato H; Mitsuzuka K; Ito A; Tsuchiya N; Arai Y; Habuchi T; Ohyama C
Clin Genitourin Cancer; 2020 Apr; 18(2):e103-e111. PubMed ID: 31810867
[TBL] [Abstract][Full Text] [Related]
14. Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.
Al Nakouzi N; Le Moulec S; Albigès L; Wang C; Beuzeboc P; Gross-Goupil M; de La Motte Rouge T; Guillot A; Gajda D; Massard C; Gleave M; Fizazi K; Loriot Y
Eur Urol; 2015 Aug; 68(2):228-35. PubMed ID: 24837187
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Novel Hormone Agents in the Treatment of Metastatic Castration-resistant Prostate Cancer: A Real-world Retrospective Study.
Li JR; Wang SS; Chen CS; Yang CK; Lu K; Cheng CL; Hung SC; Chen SY; Hsu CY; Chiu KY
Anticancer Res; 2022 Oct; 42(10):4857-4866. PubMed ID: 36191989
[TBL] [Abstract][Full Text] [Related]
16. Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
Suzuki H; Castellano D; de Bono J; Sternberg CN; Fizazi K; Tombal B; Wülfing C; Foster MC; Ozatilgan A; Geffriaud-Ricouard C; de Wit R
Jpn J Clin Oncol; 2021 Aug; 51(8):1287-1297. PubMed ID: 33738495
[TBL] [Abstract][Full Text] [Related]
17. SRD5A gene polymorphism in Japanese men predicts prognosis of metastatic prostate cancer with androgen-deprivation therapy.
Shiota M; Fujimoto N; Yokomizo A; Takeuchi A; Itsumi M; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
Eur J Cancer; 2015 Sep; 51(14):1962-9. PubMed ID: 26169017
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.
Azad AA; Eigl BJ; Murray RN; Kollmannsberger C; Chi KN
Eur Urol; 2015 Jan; 67(1):23-29. PubMed ID: 25018038
[TBL] [Abstract][Full Text] [Related]
19. Real-World Cabazitaxel Use and Outcomes in Metastatic Castrate-Resistant Prostate Cancer: The Impact of Response to First ARPI.
Watson AS; Gagnon R; Batuyong E; Alimohamed N; Lee-Ying R
Clin Genitourin Cancer; 2022 Oct; 20(5):496.e1-496.e9. PubMed ID: 35599196
[TBL] [Abstract][Full Text] [Related]
20. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
